Artera

ArteraAI is a web-based precision medicine platform for clinicians that applies multimodal AI to digital pathology images and clinical data to generate predictive and prognostic insights for prostate cancer treatment decisions.

Key capabilities include:

• Biopsy-based testing for localized prostate cancer, producing risk stratification such as 10-year metastasis risk and prostate cancer specific mortality, plus predictions of therapy benefit (including hormone therapy, ADT)
• Post-radical prostatectomy (Post-RP) testing to support decisions for patients with biochemical recurrence, including insight into potential benefit of adding short-term ADT to radiation in salvage settings
• Clinician ordering portal for uploading digital biopsy images and receiving standardized reports, with results typically available in 1 to 3 days after specimen receipt
• Models trained on thousands of patients and tens of thousands of pathology slides, validated across multiple Phase 3 randomized trials

Pricing: Unknown.

Notable for receiving U.S. FDA De Novo marketing authorization and FDA Breakthrough Device Designation for AI-powered prognostication in nonmetastatic prostate cancer, and for inclusion in NCCN Clinical Practice Guidelines (since 2024) for predictive and prognostic performance.